Acorda Shares Fall as Court Denies Injunction Request in Patent Case -- Market Mover
26 7월 2018 - 3:36AM
Dow Jones News
Acorda Therapeutics Inc. (ACOR) were down 14.8%, to $24.45,
Wednesday afternoon as a federal appeals court denied the company's
motion for an injunction in its patent litigation with generic drug
companies. In 2017, after a district court upheld one patent for
multiple sclerosis treatment Ampyra, but invalidated four others,
Acorda said it would cut about 20% of its workforce. If the appeals
court doesn't overturn the district court's decision by July 30,
"multiple generic drug manufacturers may decide to launch at-risk
generic versions of Ampyra," the company said in a filing.
(josh.beckerman@wsj.com)
(END) Dow Jones Newswires
July 25, 2018 14:21 ET (18:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Hikma Pharmaceuticals plc (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Hikma Pharmaceuticals Plc. (PC) News Articles